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Statins are highly effective for lowering low-density lipoprotein (LDL) cholesterol and
reaching LDL targets, but have a limited impact on triglycerides and high-density lipopro-
tein (HDL) cholesterol. In this issue of the journal, Laforest et al. demonstrate that high
triglyceride and low HDL-cholesterol concentrations are frequent in patients treated with
hypolipidaemic agents, mostly statins [1]. In this study, patients with high triglycerides
and low HDL-cholesterol also had more additional risk factors, in particular diabetes and
hypertension. These ﬁndings raise questions about the relevance of lipid disturbances with
statin treatment in high-risk patients.
Is there any point in paying attention to hypertriglyceridemia and low HDL-cholesterol
in these patients? Studies in families with premature coronary disease have indeed shown
that a low HDL level was the most common abnormality and was most often associated
with Hypertriglyceridemia [2]. In recent statin trials in high-risk patients, the preva-
lence of an HDL-cholesterol concentration less than 43mg/dl was high, between 40%
[3] and 60% [4]. Low HDL-cholesterol was predictive of major cardiovascular events.
In the placebo arm of the Heart protection study (HPS), patients with HDL-cholesterol
less than 35mg/dl had a 43% higher risk than those with HDL-cholesterol greater than
43mg/dl [4]. Treatment with simvastatin decreased this gap only moderately (33% higher
risk for HDL-cholesterol less than 35mg/dl while on statin treatment). An excess of risk
remained in patients with low HDL-cholesterol receiving a high dosage of statin and in
 Calciﬁed constrictive pericarditis can hide other cardiac diseases!, BosserG., Maurier F., Juillière Y., doi:10.1016/j.acvd.2008.11.005.
 This editorial, which refers to the following article, was absent from volume 102, issue 1, where the article originally appeared. The
publisher regrets the error. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with
hypolipidaemic drugs, Laforest L., Souchet T., Moulin P., Ritleng C., Desamericq G., Le Jeunne P., Schwalm M.-S., Van Ganse E.,
doi:10.1016/j.acvd.2008.06.021.
∗ Fax: +33299289587.
E-mail address: francois.paillard@chu-rennes.fr.
1875-2136/$ — see front matter © 2008 Elsevier Masson SAS. All rights reserved.
doi:10.1016/j.acvd.2008.12.001
1t
7
d
i
d
w
(
o
d
l
l
i
d
L
i
t
i
w
w
M
5
h
e
a
c
t
(
f
E
h
i
t
p
p
o
o
c
a
e
(
r
A
t
e
o
o
A
o
w
c
W
a
a
o
m
u
s

i
S
H
2
r
i
a
i
i
w
m
w
r
t
c
p
a
e
a
b
c
I
n
f
h
A
r
u
w
i
t
l
e
e
A
d
i
i
m
m
m
t
M
t
c
o
e
a
c
n
i
t
c
o66
hose with a LDL-cholesterol concentration less than
0mg/dl in the Treating to new targets (TNT) trial [3]. Epi-
emiological studies have reported a 20 to 30% increase
n cardiovascular risk for each 10mg/dl (0.26mmol/l)
ecrease in HDL-cholesterol level [5]. Even in subjects
ith spontaneously very low LDL-cholesterol concentrations
< 60mg/dl), HDL-cholesterol is an independent predictor
f coronary risk, with a 10% risk increase for every 10mg/dl
ecrease in HDL-cholesterol [6].
Another point to be emphasized is the growing preva-
ence of metabolic syndrome (MS). Hypertriglyceridemia and
ow HDL-cholesterol are two of the ﬁve criteria in the def-
nition of MS [7]. In patients with MS, Hypertriglyceridemia
erives from an increased production and secretion of very
DL triglycerides by the liver, which are induced by an
ncreased ﬂux of free fatty acids from the abdominal fat to
he liver and/or a higher activity of stearoyl-coA desaturase
n the liver [8]. A lower level of HDL-cholesterol in patients
ith MS is related mainly to hypercatabolism of HDL-apo A-1,
hich is negatively correlated with plasma adiponectin [9].
S is very often found in high-risk patients. In the TNT trial,
6% of the patients had MS and these individuals had a 44%
igher risk of cardiovascular events [10]. Both Hypertriglyc-
ridemia and low HDL-cholesterol were each associated with
n increased risk. In patients with MS, the increased risk of a
ardiovascular event was reduced signiﬁcantly with atorvas-
atin 80mg by 29% beyond that achieved with a lower dosage
atorvastatin 10mg), and a greater risk reduction was found
or each additional component of MS [10]. Unfortunately, the
uroaspire surveys in patients with coronary artery disease
ave shown that the prevalence of abdominal obesity has
ncreased steadily from 42 to 55% of the population during
he past 12 years [11].
Physician are thus more and more frequently facing a
roblem of high triglycerides or low HDL-cholesterol in
atients with vascular disease. Should the clinician ignore it
r try to improve it? Brown et al. reported a meta-analysis
f 23 studies evaluating the combined effects on cardiovas-
ular prevention of simultaneous LDL-cholesterol lowering
nd HDL-cholesterol elevation [12]. There was a strong lin-
ar relationship between a composite lipoprotein variable
the sum of percentage HDL increase and percentage LDL
eduction) and coronary stenosis progression or regression.
similar relationship was found with clinical events. So,
here is a real basis for trying to increase HDL-cholesterol
ven after LDL-cholesterol lowering.
Lifestyle modiﬁcations remain the ﬁrst mandatory rec-
mmendation [13]. The favourable effects of exercise and
f smoking cessation in high-risk subjects are not disputed.
mong a number of positive effects on arterial physiopathol-
gy and cardiovascular outcome, they are both associated
ith a moderate increase in HDL-cholesterol [13]. Exer-
ise and diet are the cornerstone of treatment for MS [7].
hen they lead to a reduction in abdominal obesity, they
re associated with a reduction in Hypertriglyceridemia
nd an increase in HDL-cholesterol. At the moment, all
f these non-pharmacological interventions are clearly the
ost established approaches in high-risk patients with resid-
al perturbations of HDL-cholesterol or triglycerides under
tatin therapy.
Fibrates are peroxisome proliferator-activated receptor
agonists that upregulate the expression of several genes
(
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nvolved in the metabolism of HDL (apo A-I, AII, ABC A1,
R-B1) and triglycerides (lipoprotein lipase). They increase
DL-cholesterol by 5 to 10% and decrease triglycerides by
5 to 45%. Despite this favourable metabolic proﬁle, the
esults of clinical trials with ﬁbrates have been conﬂict-
ng, with a risk reduction in the Helsinki heart study [14]
nd the Veterans affairs high-density lipoprotein cholesterol
ntervention trial (VA-HIT) [15] but a non-signiﬁcant effect
n the recent FIELD trial [16]. The combination of ﬁbrates
ith statins increases the risk of hepatic but most of all
uscular toxicity. The use of gemﬁbrozil in combination
ith a statin must be avoided because of a particularly high
isk of myotoxicity [13]. The effect of adding fenoﬁbrate
o statin therapy is being assessed in the Action to control
ardiovascular risk in diabetes (ACCORD) trial in diabetic
atients.
Nicotinic acid (niacin) is the most effective available
gent for increasing HDL-cholesterol (+20%) and it also low-
rs triglycerides by 20%, LDL cholesterol by 15 to 20%
nd lipoprotein(a).These favourable metabolic effects have
een associated with a reduction in coronary events and all-
ause mortality in the Coronary drug project (CDP) trial [17].
maging studies have also reported a beneﬁt of its combi-
ation with resins or statins on atherosclerosis burden and
avourable trends in clinical events [13]. Widespread use is,
owever, limited by its adverse effects, especially ﬂushing.
new formulation combining niacin with a prostaglandin-D2
eceptor antagonist reduces ﬂushing [18] and is being eval-
ated in the HPS2-Thrive trial in coronary patients treated
ith statins.
Novel HDL-based therapies are being developed that
ncrease HDL or promote cholesterol efﬂux and reverse
ransport. These developments could open new avenues in
ipid prevention. However, circulating HDL-cholesterol lev-
ls alone represent an imperfect measure of therapeutic
fﬁcacy. Recent studies have shown that some apo A-1 and
BC A1 gene mutations did not increase cardiovascular risk
espite low HDL-cholesterol [19,20]. On the other hand,
ncreased HDL-cholesterol concentrations are not protective
n some circumstances such as with estrogen therapy. The
ost unfortunate result in the development of new lipid-
odifying treatments was the 40% increase in cardiovascular
ortality in the Investigation of lipid level management
o understand its impact in atherosclerotic events (ILLU-
INATE) trial with torcetrapib, a potent cholesteryl ester
ransfer protein inhibitor, despite a 72% increase in HDL-
holesterol concentration [21]. Even if this very unfavorable
utcome may have been induced partly by molecule-speciﬁc
ffects of torcetrapib with increases in aldosterone levels
nd blood pressure, an increase in the sole HDL-cholesterol
oncentration does not necessary mean a stimulation of the
et reverse cholesterol transport, which is the central point
n HDL-associated vascular protection [13]. Unfortunately,
he assessment of the reverse transport is nowadays only
onceivable in a research setting [22].
Statin trials have shown a beneﬁt across the whole range
f HDL-cholesterol values and up to high triglycerides values
400—500mg/dl) [3,4]. When should the physician consider
he combination of a statin with an HDL-cholesterol raising
nd/or a triglyceride-lowering agent? It has been proposed
o consider this option in the higher-risk patient (with arte-
ial disease or high-risk type 2 diabetes) with persistent
stat
[
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low HDL-cholesterol (< 35mg/dl in men and 40mg/dl in
women) and/or high triglycerides (> 250mg/dl) while on
statins and despite good adherence to lifestyle modiﬁca-
tions [23]. Specialist advice about lipids may be useful in
these circumstances.
Statins remain a cornerstone of cardiovascular preven-
tion. In the absence of data assessing the beneﬁt/risk ratio
of the combination of statins with other drugs, lifestyle
intervention is pivotal in high-risk patients with residual low
HDL-cholesterol or high triglycerides. With careful atten-
tion, some patients may beneﬁt from such a combination.
The development of new HDL-raising therapies may modify
the strategy in the future.
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